Oncotest 
is a mid sized biotechnology company located in Freiburg, near the Black Forest in Germany. During the last 20 years of our experience in the anticancer research, we have established a unique collection of human tumors from various origins. This allows us to rapidly screen your compounds for anticancer activity and to select sensitive tumors to broaden your drug development pipeline up to clinical trials.

For testing your compounds for antitumor activity, Oncotest uses a stepwise evaluation including our tumor collection, tumor selection and compound testing. Our tumor collection comprises 120 xenografts permanently growing in nude mice and more than 100 cell lines. For tumor selection, analysis of tumor gene expression is used to focus on target oriented approaches. Compound testing is the core experience of Oncotest. Our three in vitro and in vivo screens use permanent tumor cell lines (monolayer assay) or human xenografts (clonogenic assay and in vivo studies) and allows you to stepwise focus on the best lead candidate for the clinic.

Company Info

Oncotest was founded 1992 and has been quickly recognized internationally for its expertise in anticancer drug evaluation. Oncotest collaborates with many pharmaceutical and biotech companies and institutions such as the European Organisation for Research and Therapy of Cancer and the National Cancer Institute of the USA.